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Abstract: Precise replacement of diseased or dysfunctional organs is the goal of regenerative medicine and
has appeared to be a distant goal for a long time. In the field of hematopoietic stem cell transplantation,
this goal is now becoming tangible as gene-editing technologies and novel conditioning agents are entering
the clinical arena. Targeted immunologic depletion of hematopoietic stem cells (HSCs), which are at
the very root of the hematopoietic system, will enable more selective and potentially more effective
hematopoietic stem cell transplantation in patients with hematological diseases. In contrast to current
conditioning regimes based on ionizing radiation and chemotherapy, immunologic conditioning will spare
mature hematopoietic cells and cause substantially less inflammation and unspecific collateral damage
to other organs. Biological agents that target the stem cell antigen CD117 are the frontrunners for
this purpose and have exhibited preclinical activity in depletion of healthy HSCs. The value of anti-
CD117 antibodies as conditioning agents is currently being evaluated in early clinical trials. Whereas
mild, antibody-based immunologic conditioning concepts might be appropriate for benign hematological
disorders in which incomplete replacement of diseased cells is sufficient, higher efficacy will be required
for treatment and elimination of hematologic stem cell malignancies such as acute myeloid leukemia
and myelodysplastic syndrome. Antibody-drug conjugates, bispecific T-cell engaging and activating
antibodies (TEAs), or chimeric antigen receptor (CAR) T cells might offer increased efficacy compared
with naked antibodies and yet higher tolerability and safety compared with current genotoxic conditioning
approaches. Here, we summarize the current state regarding immunologic conditioning concepts for the
treatment of HSC disorders and outline potential future developments.
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Precise replacement of diseased or dysfunctional organs is the goal of regenerative
medicine and has appeared to be a distant goal for a long time. In the field of hemato-
poietic stem cell transplantation, this goal is now becoming tangible as gene-editing
technologies and novel conditioning agents are entering the clinical arena. Targeted
immunologic depletion of hematopoietic stem cells (HSCs), which are at the very root
of the hematopoietic system, will enable more selective and potentially more effective
hematopoietic stem cell transplantation in patients with hematological diseases. In con-
trast to current conditioning regimes based on ionizing radiation and chemotherapy,
immunologic conditioning will spare mature hematopoietic cells and cause substantially
less inflammation and unspecific collateral damage to other organs. Biological agents
that target the stem cell antigen CD117 are the frontrunners for this purpose and have
exhibited preclinical activity in depletion of healthy HSCs. The value of anti-CD117
antibodies as conditioning agents is currently being evaluated in early clinical trials.
Whereas mild, antibody-based immunologic conditioning concepts might be appropri-
ate for benign hematological disorders in which incomplete replacement of diseased
cells is sufficient, higher efficacy will be required for treatment and elimination of
hematologic stem cell malignancies such as acute myeloid leukemia and myelodysplastic
syndrome. Antibody−drug conjugates, bispecific T-cell engaging and activating anti-
bodies (TEAs), or chimeric antigen receptor (CAR) T cells might offer increased effi-
cacy compared with naked antibodies and yet higher tolerability and safety compared
with current genotoxic conditioning approaches. Here, we summarize the current state
regarding immunologic conditioning concepts for the treatment of HSC disorders and
outline potential future developments. © 2021 ISEH – Society for Hematology and
Stem Cells. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Biology of HSCs and HSC disorders
Adult hematopoiesis takes place in designated areas of
the bone marrow, one of the most proliferative and
metabolically active organs of the human body. The
average daily output of blood cells is estimated to be
in the range of 4−5£ 1011 total nucleated cells
(reviewed by Nombela-Arrieta and Manz [1]). A
sophisticated hierarchical arrangement relieves the rare
hematopoietic stem cells (HSCs) from the majority of
the mitotic burden, which is carried by diverse multi-
potent and lineage-restricted progenitor cells [2−8]. In
this way, HSCs can remain dormant for extended peri-
ods and are less vulnerable to damage and mutagenesis
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during cell divisions for self-renewal [9]. During a
human life span — under the constant stress of inflam-
mation and aging — mutations do occur in HSCs, and
certain genetic abnormalities provide a clonal advan-
tage [10]. The presence of mature nucleated blood cells
of clonal origin in peripheral blood without overt
hematological disease has been coined clonal hemato-
poiesis of indeterminate potential (CHIP). This condi-
tion is strongly associated with aging and can be
detected in more than 10% of individuals aged 70 years
and older [11−14]. CHIP has been linked to several
hematopoietic and non-hematopoietic disorders [11,15].
Recently, the presence of clonal myeloid cells in
peripheral blood was found to precede the onset of
acute myeloid leukemia (AML) or myelodysplastic syn-
drome (MDS) by years to decades [16,17]. AML and
MDS are malignant diseases characterized by uncon-
trolled proliferation and maturation arrest of hemato-
poietic progenitor cells, which derive from leukemia-
initiating cells (LICs) [18,19].
To our current understanding, the consecutive accu-
mulation of mutations, especially in genes encoding for
intracellular signaling proteins, transcription factors, or
epigenetic regulators, as well as chromosomal rear-
rangements, lead to profound aberrations in intracellu-
lar signaling cascades of hematopoietic stem and
progenitor cells [20,21]. These aberrations are not con-
nected to major recurring changes of the surface prote-
ome on malignant hematopoietic cells when compared
with healthy counterparts. Hence, the search for aber-
rant antigen expression profiles or universal neoanti-
gens that could be exploited for selective cell surface-
directed immunotherapy of malignant cells has
remained futile to date. Combinatorial targeting of leu-
kemia-associated surface antigens might be one
approach to circumvent the lack of truly leukemia-spe-
cific surface targets [22,23]. An alternative solution
would be the use of immunotherapy directed at surface
antigens, which are shared between malignant and
healthy hematopoietic cells such as CD117, CD123,
and CD135 [24,25]. Currently approved immunothera-
pies for the treatment of B-cell and plasma cell neopla-
sias are based on this approach as they are lineage-
directed and not malignancy-directed. Here, collateral
damage to healthy cells is taken into account and is
attenuated by appropriate measures, such as replace-
ment of immunoglobulins. Immunotherapies directed at
HSCs will cause severe bone marrow aplasia as funda-
mentally all healthy, HSC-derived hematopoiesis will
be depleted alongside malignant cells. Therefore,
replacement of hematopoiesis by hematopoietic stem
cell transplantation (HSCT) after immunotherapy would
be required.
In summary, HSC disorders such as CHIP, MDS,
and AML are considered a consequence of multiple
mutations that are acquired by HSCs or early progeni-
tor cells and that ultimately interfere with the produc-
tion of normal blood cells. Despite the major impact
on homeostasis of the individual patient, the pheno-
typic cellular changes are minor and heterogeneous,
and no broadly targetable leukemia- or MDS-specific
target antigen has yet been discovered, hence restrict-
ing the potential of surface-directed immunotherapy in
AML.
Hematopoietic stem cell transplantation for
elimination of AML and MDS stem cells
Current first-line strategies in the treatment of younger
patients with AML are aimed at remission induction,
that is, the reduction of leukemia cells in the bone mar-
row below a threshold of 5%, followed by HSCT in
most cases. Continuous administration of cytarabine in
combination with an anthracycline (“7+3 chemo-
therapy”) induces temporary remissions with regenera-
tion of healthy hematopoiesis in more than 85% of
cases [26]. Sensitivity to cytotoxic agents varies sub-
stantially, and specific mutations have only limited pre-
dictive power [20,21]. Despite successful initial
reduction of leukemia burden, disease relapses are
common without consolidation therapy. These relapses
are thought to originate from leukemia stem cells
(LSCs), that is, malignantly transformed HSCs with a
slow cycling rate and pluripotent, albeit blocked differ-
entiation potential [19,27,28]. LSCs, as well as HSCs,
are relatively refractory to cytotoxic agents and irradia-
tion and are thus difficult to eradicate by means of con-
ventional therapy. Therefore, not only specific
mutations, but depth of remission (i.e., minimal or
measurable residual disease [MRD]) indicates the
response to therapy and is a valid indicator of long-
term relapse-free survival [29]. Allogeneic HSCT is the
most effective treatment for many patients with AML
and can provide long-term disease control in up to
50% of the cases [30]. This favorable outcome is
attributed in large part to the graft-versus-leukemia
effect (GvL), that is, immunologic elimination of host-
derived hematopoiesis by donor-derived lymphocytes,
most importantly T cells and NK cells [31]. This
effect, in essence, can be regarded as graft-versus-host
disease (GVHD) against hematopoietic cells.
To enable engraftment of allogeneic HSCs, three
indispensable prerequisites need to be fulfilled: (1)
freeing of space for incoming HSCs in the bone mar-
row microenvironment (the so-called stem cell
“niche”); (2) immunosuppression of the host to prevent
rejection of the graft; (3) reduction of remaining leuke-
mia cells [32]. To achieve these, transplant recipients
are conditioned with a combination of cytotoxic agents
including antimetabolites (e.g., cytarabine, fludarabine),
alkylating agents (busulfan, cyclophosphamide), and
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irradiation [33]. Additionally, alloreactive host and
donor T cells are often ablated by use of antibodies. A
hallmark and a major disadvantage of conventional
conditioning regimens is the lack of specificity as
major damage is inflicted to mature and immature,
healthy and diseased hematopoietic and non-hematopoi-
etic cells. Advantages of the currently used condition-
ing regimes include the decades of experience that
have been accumulated as well as comparably inexpen-
sive drug costs. Importantly, laborious customization in
the sense of personalized medicine is not required.
However, the risks of hematopoietic stem cell trans-
plantation with conventional conditioning regimes out-
weigh the benefits in almost all use case scenarios,
with few exceptions such as malignant hematological
diseases and certain rare inherited or acquired immune
or blood disorders. Although conditioning regimes have
been gradually attenuated in past decades, they still
cause relevant toxicity in several organ systems. Toxic-
ity in the bone marrow microenvironment leads to pro-
longed cytopenia in peripheral blood and release of
pro-inflammatory mediators, which in turn alter the
immunologic state of the incoming graft. The develop-
ment of chronic GVHD is a severe consequence of this
damage-associated immune response [34]. In addition,
cytotoxic regimens can cause other severe acute or
delayed complications such as seizures, damage to kid-
ney or liver, hemorrhagic cystitis, and secondary
malignancies [33]. More refined conditioning techni-
ques are therefore needed and could enable HSCT with
substantially reduced toxicity. In the setting of AML
and MDS, this could bring the prospects of HSCT to
groups of patients that are currently excluded because
of the high risk of adverse effects at advanced age or
in the presence of comorbidities.
Current state of immunotherapies for AML
Despite an ever-extending list of successful immuno-
therapies for hematological cancers and also some solid
tumors, AML and MDS have remained difficult targets,
as reviewed elsewhere [24,35−37]. To date, the anti-
CD33 antibody−drug conjugate (ADC) gemtuzumab
−ozogamicin is the only immunotherapy approved for
clinical application in a subset of AML patients in
combination with classic “7+3 chemotherapy" [38].
More recently, the anti-CD70 antibody cusatuzumab
has exhibited promising activity in combination with
hypomethylating agents (HMAs) [39]. Other immuno-
therapeutic efforts have failed or are in early clinical
stages, such as the combination of HMA with anti-
CD47 antibodies or immunotherapeutic agents directed
at the surface antigens CD33, CD123, and CXCR4
[24,25,40−43].
Because of the phenotypic similarity between HSCs/
progenitor cells and LSCs, the alternative concept,
based on radical and complete immunologic elimina-
tion of both healthy and diseased hematopoiesis, fol-
lowed by HSCT from an allogeneic donor, is gaining
momentum. In the absence of specific leukemia-defin-
ing antigens in AML and MDS, this approach could
eventually bring the advantages of immunotherapy to
patients with stem cell disorders [44]. In our view, the
most promising target antigen to date is CD117 (c-Kit),
the cognate receptor for stem cell factor (SCF).
Identification of CD117 as a promising target for
immunologic conditioning
A long list of surface antigens and potential (intracellu-
lar) HLA-presented neo-antigens have been explored
for immunologic targeting of HSCs and leukemic
blasts. All of these antigens have peculiar advantages
and disadvantages, as reviewed elsewhere [45]. In gen-
eral, targets that are more highly expressed on matur-
ing cells, such as CD33 and CD45, may be associated
with unwanted adverse effects such as myelosuppres-
sion [46]. CD33 is additionally vulnerable to slow
receptor internalization and not essential for cell sur-
vival [47,48]. Hence, the clinical activity of anti-CD33
agents such as gemtuzumab−ozogamicin is limited.
Targets that are essential for survival of HSCs and
blasts, for example, CD117, CD123 (interleukin-3
[IL3] receptor a), and CD135 (FLT3), might be more
attractive as dependence on the respective growth fac-
tors SCF, IL3, and FLT3-ligand is difficult to compen-
sate for, even by malignant cells. CD117 is the most
widely explored target for immunologic conditioning of
healthy HSCs and, thus, also a promising target for
immunologic depletion of malignant HSCs/LSCs.
Physiological functions of SCF/CD117 in non-
hematopoietic tissues
CD117 (also c-Kit or stem cell factor receptor [SCFR])
is an evolutionary ancient membrane receptor tyrosine
kinase (RTK) that is crucial for ontogenesis and
homeostasis of the individual [49]. SCF is the only
cognate ligand and induces diverse functions in various
organs: SCF/CD117 signaling is mostly known for its
role in hematopoiesis, but other features such as devel-
opment of the CNS, germ cell maturation, cell migra-
tion, and intestinal motility equally rely on CD117
signaling [49−51]. SCF is produced by various cell
types as a glycosylated transmembrane protein and
released by proteolytic cleavage. Alternative splicing
results in a separate isoform that lacks the cleavage
site and remains membrane bound. Soluble SCF gener-
ates gradients that are involved in migration of differ-
ent cells, such as melanocytes. Cell surface−bound
SCF expressed by endothelial cells of the bone marrow
or perivascular stroma cells of the bone marrow is
required for maintenance/self-renewal of HSCs [52].
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Major insights into the function and significance of
SCF/CD117 signaling have been gained from the study
of mice with naturally occurring mutations in the
respective genes [53−55]. Homozygous SCF or
CD117-deficient mice are not viable because of severe
perinatal anemia. Similarly, there are no known cases
of humans with homozygous SCF or CD117 deficiency.
Mice with heterozygous null mutations or homozygous
variants in the kit gene can be viable and fertile; how-
ever, they present with phenotypic changes such as
abnormalities in fur pigmentation and reduced blood
cellularity [56]. In humans, the syndrome of piebaldism
is connected to heterozygous missense mutations in the
human KIT gene [57,58].
Physiological functions of SCF/CD117 in
hematopoiesis
High levels of CD117 expression are characteristic of
mature mast cells, where SCF is responsible for main-
tenance, migration, and activation [59]. In addition,
SCF/CD117 signaling is crucial for hematopoietic stem
and progenitor cells in fetal and adult hematopoiesis
[60]. HSCs express high levels of CD117, and mainte-
nance of adult HSCs depends on expression of SCF in
the bone marrow microenvironment, specifically by
endothelial and perivascular stromal cells [52]. HSCs
and progenitor cells with CD117 loss-of-function var-
iants have a competitive disadvantage compared with
wild-type cells, even of xenogeneic origin [55,56].
Functionally, SCF/CD117 signaling is involved in the
regulation of self-renewal, survival, proliferation, and
differentiation of HSCs and stemness of progenitor
cells in general [61,62]. Even minor changes in signal-
ing through the SCF/CD117 axis have a major impact
on cell cycling and differentiation patterns. In mice,
phenotypically defined HSCs exhibit differential
CD117 expression within a log scale range. Of these
cells, higher CD117 expression is linked to increased
cycling rate, higher cell output, lower long-term differ-
entiation potential, and megakaryocyte lineage bias
[63,64].
Expression patterns in mice and humans
The data on CD117 expression in human tissues are
inconsistent. Whereas CD117 is required for organo-
genesis of different organs, presumably functioning as
a guiding path for migrating cells such as melanocytes,
only a few mature cell types consistently express high
levels of CD117 (Figure 1) [49,65]. In addition to
hematopoietic stem cells and mast cells, interstitial
cells of Cajal (ICCs) and melanocytes, epithelial cells,
and certain cells in the reproductive organs are highly
positive for CD117 [66−68]. In a recent publication,
we used immunohistochemistry to compare CD117
expression patterns in several vital organs of humans
and mice [69]. In summary, we found that low-level
CD117 expression is more common than generally
acknowledged and is, for example, present in tubular
epithelial cells of the kidney or ovarian follicular cells.
Expression patterns in the central nervous system are
Figure 1. CD117 expression as demonstrated by immunohistochemistry or immunofluorescence microscopy in healthy adult human tissue [65
−71].
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not entirely elucidated, but findings indicate the pres-
ence of rare cerebellar CD117-positive cells and some
cells in the hippocampus and eye [65,70,71]. Further-
more, tissue expression patterns in mice and humans
are generally comparable and therefore provide evi-
dence for the mouse as a likely valid model to study
on-target, off-tumor toxicity of anti-CD117−directed
immunotherapies.
CD117 in cancerogenesis
Because of the inherent functions in regulation of stemness,
proliferation, and cell cycling, CD117 is a proto-oncogene
and involved in cancerogenesis of different tumor entities
[72]. Oncogenic driver mutations in CD117 may occur in cell
types that inherently express CD117. In this way, gastrointes-
tinal stroma tumors (GISTs) develop from ICCs, mastocytosis
frommast cells, melanoma frommelanocytes, and acute mye-
loid leukemia from HSPCs. Under physiological conditions,
soluble or membrane-bound SCF binds to the distal extracel-
lular domains of CD117 and induces dimerization and auto-
phosphorylation of CD117 [73]. Mutational hotspots include
a tyrosine kinase domain (e.g., D816V, exon 17) or the intra-
cellular (exon 11) or extracellular (exons 8 and 9) juxtamem-
brane domains [49,74,75]. Mutations in exon 9 and 11
increase ligand-independent receptor dimerization and/or
reduced suppression of the kinase domain [49,76]. Mutations
in the tyrosine kinase domain are thought to increase the affin-
ity of the receptor to ATP and limit inhibitory effects of the
juxtamembrane domain in a monomeric state [77,78]. There
are predilections for specific mutations between different can-
cer types, however, oncogenic mutations typically result in
gain-of-function phenotypes and permanently active CD117
signaling [49,74,75]. Only recently, CD117 was described as
a dependence receptor with pro-apoptotic functions in the
absence of SCF [79]. This observation might help to explain
why loss of CD117 expression confers a survival advantage
in some cancer types such as neuroblastoma [79]. Impor-
tantly, mutations influence subcellular localization of the
receptor and can reduce CD117 surface expression levels
[49]. For an in-depth analysis of the pathophysiological func-
tions of specific CD117 mutations in diverse human malig-
nancies, we refer to detailed reviews on the topic
[49,72,74,75].
Human CD117 was first identified in blasts of an AML
patient, and expression of CD117 in acute myeloid leukemia
occurs in about 85% of AML cases as determined by flow
cytometry [80,81]. Mutations in CD117 are prognostically
relevant in the group of core-binding factor (CBF) leukemias
with t(8;21) or inv(16) [82]. Despite the absence of direct
experimental proof, it is highly likely that LSCs are CD117
positive, at least in cases of CD117-positive AML. Moreover,
paracrine and autocrine expression of SCF by tumor
cells, including AML blasts, has been reported, and
experimental data indicate that SCF signaling might be
an essential survival factor for LSCs [83−86]. These
properties position CD117 as a promising target for
immunotherapy of AML as it might be an unlikely can-
didate for antigen-negative escape.
Anti-CD117 conditioning: preclinical data from
rodent models
After the concept of antibody-based immunologic condition-
ing was originally conceived, feasibility was analyzed in ani-
mal models, mostly in rodents. In preclinical studies,
spearheaded by the groups of Weissman and Shizuru at Stan-
ford University, CD117 has emerged as a most promising tar-
get. In mice, the transplantation of HSCs into unconditioned
immunocompromised recipients depends on the availability
of HSC niche space as larger numbers of transplanted HSCs
do not result in a linear increase of donor chimerism [87,88].
SCF/CD117 signaling constitutes a crucial aspect of the HSC
niche in bone marrow [52,62,89,90]. With the generation of
the anti-CD117 antibody ACK2, a novel experimental tool
became available that specifically blocks ligation of SCF to
CD117 and hence enables analysis of the physiological effects
of CD117 signaling in vivo [91,92]. Other anti-mouse CD117
antibodies such as ACK4, 2B8, and 3C11 bind to different
epitopes and do not block SCF-induced receptor dimerization
[92−94]. Importantly, the blocking antibody ACK2 is not
cross-reactive with human CD117. In mice, administration of
ACK2 induced temporary depletion of HSPCs in the bone
marrow and subsequent reduction of mature myeloid and ery-
throid cells in the peripheral blood [92]. When used in a trans-
plantation setting, blocking of CD117 by ACK2 caused an
increased availability of HSC “niche” space, which facilitated
engraftment of donor-derived HSCs and resulted in substan-
tially higher donor chimerism [94]. ACK2 was initially
described as a purely blocking antibody without depleting
functionality [91,92]. However, in a more recent publication,
ACK2 Fab fragments that were engineered to lack the IgG
stalk were less efficient in facilitating donor HSC engraftment
compared with the full IgG2b antibody. This indicates that
blockade of the SCF/CD117 interaction is not the only mode
of action but that immune effector functions such as comple-
ment-mediated cell death and antibody-dependent cytotoxic-
ity contribute as well [95]. With ACK2 as sole conditioning
agent, stable donor chimerism was achieved only in immuno-
compromised recipients (e.g., Rag1-, FancA-, or Fancd2-defi-
cient animals) and in a syngeneic setting [87,94,96]. The
presence of adaptive host immunity prevents engraftment
even across minor immunologic barriers (e.g., CD45.1 to
CD45.2) [87,95]. To enable transplantation in immunocompe-
tent mice, different combination strategies have been
employed. Low-dose irradiation in combination with ACK2
proved to efficiently decrease HSC numbers and permit trans-
plantation of bulk bone marrow cells into immunocompetent
congeneic mice [97]. However, combination with irradiation
nullifies one of the main advantages of immunologic condi-
tioning, that is, the reduction of toxicity and inflammatory
stimuli.
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An elegant concept was established by combination
of ACK2 with blockade of the CD47-SIRPa axis. The
“don‘t eat me signal” CD47 is ubiquitously expressed
to prevent attacks on healthy cells by phagocytes.
Importantly, HSCs are not strictly resident in the bone
marrow niche, and a certain fraction is found circulat-
ing in peripheral blood at any given time. During the
transition of HSCs from the bone marrow to peripheral
blood, CD47 is upregulated to prevent loss of rare
HSCs to attacks from phagocytes [98]. Similarly, upre-
gulation of CD47 occurs in AML, and blockade with
anti-CD47 antibodies mediates phagocytic elimination
of LSCs but not HSCs [99,100]. Concomitant blockade
of CD47 potentiates the activity of ACK2 by enhancing
IgG-receptor−mediated phagocytosis of HSCs, hence
enabling immunologic conditioning of immunocompe-
tent animals [95]. In a separate study, administration of
anti-CD47 antibodies increased the efficacy of in utero
HSC depletion and newborn transplantation [101,102].
When T cells are depleted in addition, transplantation
across minor immune barriers can be accomplished
[95]. The CD47−SIRPa axis is a subject of intensive
research, and our understanding of its role in immunity
is rapidly expanding [103]. Therefore, other yet unde-
fined mechanisms might contribute to the efficacy of
CD47 blockade in immunotherapy.
In a more refined experimental setup, the Weissman
group recently developed an all antibody-based condi-
tioning regime, which is based on blockade of CD117
and CD47 in combination with antibody-mediated lym-
phocyte depletion. This six-antibody cocktail allowed
for haplo-identical or even fully MHC-mismatched
transplantation between different immunocompetent
mouse strains [104]. Despite the immunologic differen-
ces, no signs of GVHD occurred, and central immuno-
logic tolerance was induced by removal of host-derived
T cells with reactivity against donor antigens. Conse-
quently, HLA-mismatched solid-organ transplantation
was feasible, and mice were able to mount an adequate
humoral immune response 6 weeks after transplanta-
tion. With this concept, stable chimerism of more than
50% was reproducibly achieved.
Anti-human CD117 conditioning: preclinical data
All of the data summarized above were generated with
the anti-mouse CD117 antibody ACK2, which is not
cross-reactive to human CD117. The mouse anti-human
CD117 antibody SR-1 (IgG2a) has comparable proper-
ties as it blocks binding of human SCF and is a weak
inducer of antibody-dependent cytotoxicity (ADCC)
[105]. SR-1 was developed into a humanized, aglycosy-
lated IgG1 antibody with reduced effector functionality
and favorable pharmacokinetic properties, subsequently
termed AMG191 and currently licensed as JSP191
[106]. Similar to ACK2 in the mouse setting, JSP191
transiently depletes HSPCs in fully immunocompetent
cynomolgus monkeys after a single intravenous injec-
tion [107]. When administered to macaques in a differ-
ent non-human primate model, SR-1 exhibited only
limited efficacy in combination with busulfan or total-
body irradiation [108]. Importantly, no effects were
observed on circulating mature white blood cells or
non-hematopoietic organs. Likewise, in xenografted
humanized mice, a single injection of JSP191 caused
subtotal depletion (< 5%) of human CD45+ cells in
most animals and enabled engraftment of HSCs from
an unrelated donor [107]. Importantly, mouse SCF is
cross-reactive to human CD117, albeit with lower bio-
logical activity [109−113]. Nevertheless, endogenous
mouse SCF levels are sufficient for engraftment of
human cells in immunodeficient mice [114,115]. In
view of these promising experimental data, it seems
probable that antibody-based conditioning regimens
will change HSC transplantation in benign hematologi-
cal disorders in the near future.
Taken together, the cumulative data indicate that
purely antibody-based conditioning approaches lead to
stable mixed chimerism and immune tolerance between
donor and host immune cells. However, complete eradi-
cation of the host hematopoietic system is not achieved,
in part possibly because of lack of activation of donor
leukocytes in the absence of an inflammatory microenvi-
ronment. Therefore, the potency required for condition-
ing in hematopoietic malignancies will likely not be
sufficient, as depletion of virtually all malignant stem
cells will be required for long-term disease control.
Indeed, in a patient-derived xenograft (PDX) model,
poor-risk MDS cells were mostly resistant to treatment
with JSP191, while lower-risk MDS cells were partly
susceptible [83]. These data might also indicate that
external survival signals are less important for higher-
grade myeloid malignancies, which are therefore less
susceptible to mere blockade of CD117. To modulate
the efficacy of CD117-targeting agents, different con-
cepts have been devised.
Anti-CD117 IgG antibodies
The CD117 expression profile is reason for concern for
highly effective immunotherapeutic agents. The initial
development of JSP191 from the mouse antibody SR-1
was therefore aimed at generating an agent with opti-
mized pharmacokinetics, high blocking activity, and
minimal effector functionality in the sense of antibody-
dependent cellular cytotoxicity (ADCC), antibody-
dependent cellular phagocytosis (ADCP), and comple-
ment-dependent cytotoxicity (CDC). The unmodified
humanized SR-1 IgG1 isoform (hSR-1 IgG1) was dis-
carded because of the high affinity to activating Fc-
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receptors and partly agonistic properties on CD117.
Prototypes of humanized SR-1 antibodies in IgG2
(hSR-1 IgG2) format exhibited partly activating proper-
ties and induced clumping of cells, while SR-1 in the
human IgG4 framework (hSR-1 IgG4) had adverse bio-
chemical properties as it aggregated during purification
[106]. Deglycosylation of the humanized IgG1 antibody
(hSR-1 aIgG1) resulted in a molecule with reduced
effector functionality and desired pharmacodynamic
and pharmacokinetic properties [106]. However, resid-
ual activation of macrophages occurs with aglycosy-
lated antibodies and might contribute to the effects of
JSP191. More recently, several separate human anti-
CD117 antibodies were generated and found to have




Following the favorable toxicity profile of blocking
antibodies, the next generation of anti-CD117 targeted
therapies was designed with increased effector func-
tionality. Immunotoxins and ADCs deliver a cytotoxic
payload specifically to antigen-positive cells. Two dif-
ferent cytotoxic agents were linked to anti-CD117 anti-
bodies and tested in preclinical trials. First, the anti-
mouse CD117 antibody 2B8, linked to the protein sap-
orin, efficiently cleared HSCs from the bone marrow
compartment and enabled engraftment of allogeneic
mouse stem cells, resulting in up to 80% donor chime-
rism [120]. In the experimental system tested (i.e., sin-
gle injection, readout at day +8), functional HSCs were
subtotally reduced (>99%). Interestingly, other CD117+
progenitor cells were only mildly affected (<50%
reduction of total CD117+ cells/femur). Expectedly,
mature myeloid cells and lymphocytes were resistant to
this therapy, and immunity to viral infection remained
intact. Saporin-enhanced anti-CD117 antibodies were
also used for conditioning of mice with Fanconi anemia
and enabled immunologic tolerance to skin allografts in
separate studies [121,122]. Importantly, anti-human
CD117-saporin immunotoxins eliminated human HSCs
in humanized mice in a proof-of-principle experiment
[120]. A second anti-human ADC was generated by
linkage of the RNA polymerase inhibitor amanitin to
an anti-CD117 IgG. Even though definitive results are
not published yet, early data proved the effectiveness
of depletion of functional HSCs in humanized mice
and non-human primates [123].
Bispecific T cell−engaging and −activating
antibodies
The bispecific T-cell engager (BiTE) blinatumomab
(CD19£CD3) was the first clinically approved product
of its class and has had a major impact on the
treatment of acute B-cell neoplasias [124]. A high-
affinity single-chain variable fragment (scFv) for a
given lineage marker is connected by a short linker
peptide to a lower affinity, activating scFv for CD3,
resulting in a tandem scFv [125]. In this way, cytotoxic
T lymphocytes are redirected (independently of TCR-
activation) against antibody-covered target antigen-pos-
itive malignant cells, where they induce T cell−medi-
ated killing. Because of the absence of the Fc region,
conventional antibody-mediated functions such as com-
plement activation, facilitation of phagocytosis, and
long half-life caused by cellular re-cycling are lacking
[125]. T cell−mediated immunity against LSCs is the
fundamental mode of action of the graft-versus-leuke-
mia effect in allogeneic stem cell transplantation and
donor-lymphocyte infusions. Therefore, the concept of
exclusively redirecting T cells against HSCs by use of
a tandem scFv format is appealing. A major advantage
of this drug class is the short in vivo half-life of
approximately 90 min as this property enables immedi-
ate cessation of anti-HSC activity when clinically
desired, for example, for reasons of toxicity or subse-
quent transfusion of the donor graft [125,126]. Other
bispecific formats, such as dual affinity-retargeting
antibodies (DARTs) and tetravalent bispecific tandem
antibodies (tandAbs), exhibit different pharmacokinetic
properties and might convey benefits in other clinical
scenarios [127]. Importantly, not only T cells can be
recruited to a given target cell by use of bispecific dia-
bodies. Promising reports exist for redirection of natu-
ral killer (NK) cells by targeting the surface antigen
CD16 or NKp46 [128,129]. Several bispecific diabodies
are in clinical development for the treatment of AML
and target CD33 and CD123 among others (reviewed
in Guy and Uy [130]). A CD117£CD3 bispecific dia-
body in tandem scFv format was recently developed by
us and found to have biological activity against healthy
HSCs and AMLs (Kiefer et al., unpublished data).
More specifically, CD117-positive cells were selec-
tively eliminated by T cells in presence of the
CD117£CD3 antibody while CD117-negative cells
were spared. In conclusion, bispecific diabodies com-
bine advantages of antibody-based therapies, such as
comparably simple large-scale production, storage, and
controllability, with the efficacy of T-cell immunother-
apy and might therefore be ideal candidates for use in
immunologic conditioning regimes [131].
Anti-CD117 CAR T cells
Yet another revolution in the treatment of B-cell malig-
nancies was the approval of gene-engineered, patient-
derived, chimeric-antigen receptor (CAR) T cells in
2017 [132]. CAR T cells are genetically engineered to
carry an antibody domain on their surface, which is
linked to an intracellular signaling moiety. On ligation
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of the target antigen, CAR T cells are activated, which
causes proliferation and target cell lysis. The transla-
tion of this approach for the treatment of AML has
several limitations and pitfalls as discussed below.
However, several concepts have emerged that exhibit
convincing preclinical or early activity [43]. Building
on the fundamental studies that established CD117 as a
potential target for immunologic conditioning, mouse
anti-CD117 CAR T cells were developed in a proof-of-
concept study [133]. After lymphodepleting chemother-
apy, immunocompetent mice were treated with anti-
CD117 CAR T cells, which were co-transduced with
CXCR4 for increased homing to the bone marrow.
CAR T cells were depleted after 10 days, and trans-
plantation of HSPCs from a congenic mouse strain
ensued. This treatment protocol enabled stable mixed
chimerism of approximately 40% with no relevant
reported side effects. However, there are many inherent
limitations to this study (e.g., depletion of CAR T cells
after 10 days, inherently lower activity of mouse CAR
T cells compared with those from humans) that might
lead to underestimation of the potency of anti-CD117
CAR T cells in the treatment of AML.
We recently developed anti-human CD117 CAR T
cells that exhibited near-total depletion of healthy
HSCs and AML blasts in vitro and in vivo in human-
ized patient-derived xenograft systems [69]. As dis-
cussed below, we anticipate that CAR T cells might
provide the highest effector activity.
Risk−benefit estimation of different anti-CD117
modalities
An ideal compound for immunologic conditioning
would combine the following characteristics: (1) high
cytotoxic efficacy for profound depletion of target
cells; (2) a favorable toxicity profile resulting from a
lack of expression of the target antigen by non-hemato-
poietic cells; (3) the option to control and terminate
cytotoxic activity when clinically desired; and (4) the
option for bulk production without the need for indi-
vidualization. Bare humanized IgG immunoglobulins
are on one side of the spectrum and are relatively easy
to produce, store, and administer (Figure 2A). How-
ever, the serum half-life of 21 days is a disadvantage if
side effects occur or subsequent transplantation with
antigen-positive donor cells is desired. CAR T cells, on
the other hand, are on the opposite end of the spec-
trum. As “living drugs,” they are highly effective and
expand in vivo until clearance of target cells is accom-
plished. Inherent disadvantages are the lack of clini-
cally solid-proven means to control and terminate CAR
T-cell activity. Although different approaches have
been devised, such as antibody-based clearance via
transgenic expression of surface molecules (e.g.,
RQR8, CD19) or the caspase-9−based suicide system,
clinical proof of high efficacy is lacking [134−136].
Another obvious disadvantage is the high demand of
personalization that is required for autologous CAR T-
cell production.
Timing of immunologic conditioning in relation to
standard-of-care chemotherapy will be critical in early
clinical trials of patients with AML and MDS. In our
view, as outlined in Figure 2B, immunologic condition-
ing should be applied at an early time point, for exam-
ple, in first complete remission (CR1), possibly in an
MRD-positive situation. Sampling of autologous patient
T cells at first clinical presentation might be challeng-
ing, and production time of CAR T cells might exceed
the available time window before relapse. Possibly,
progress in the development of universal donor CAR T
cells might mitigate these problems. Modified immuno-
globulin-based therapies such as ADC and bispecific
tumor and T cell−engaging antibodies are between
those two poles. In our view, T cell−engaging antibod-
ies combine good pharmacodynamic properties (i.e.,
high cytotoxic activity) with advantageous pharmacoki-
netics (i.e., good controllability) because of the short
half-life. Obviously, patients will require continuous
infusion of the drug for a treatment duration in the
range of days to weeks; however, this is already rou-
tinely performed in clinics with blinatumomab. The
number of ADCs approved for clinical application is
expanding, especially for hematological malignancies,
in combination with conventional chemotherapy. Mech-
anistically, the cytotoxic payload amanitin or saporin
interferes with protein biosynthesis. The susceptibility
of slowly cycling and metabolically inactive HSCs/
LSCs to these toxins needs to be determined.
SCID as a “model bridge” to clinics
Building on growing evidence emphasizing the role of
mast cells in inflammatory processes as wells as on the
success of the tyrosine kinase inhibitor imatinib,
Amgen developed a humanized aglycosylated version
of the mouse anti-human CD117 antibody SR-1 as indi-
cated before. Development of the compound, initially
intended for depletion of mast cells in inflammatory
diseases, was halted after a phase 1 trial. Shizuru
et al., who were behind the preclinical trials demon-
strating immunologic niche clearance by anti-CD117
IgG in mice, realized the clinical potential of the anti-
body. Accordingly, a first clinical trial is ongoing in
which children with severe combined immunodefi-
ciency (SCID) received JSP191 as sole conditioning
agent prior to allogeneic stem cell transplantation
[137]. These children are the predestined population
for immunologic conditioning for several reasons: (1)
the severity of adverse effects of irradiation- or chemo-
therapy-based conditioning prohibits use in these
highly immunocompromised patients; (2) absence of an
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Figure 2. Cell population kinetics in bone marrow and effector strength of anti-CD117 immunotherapies. (A) Function, effector strength, and
toxicity of different anti-CD117 immunotherapies. From left to right, anti-CD117 antibodies in combination with anti-CD47 antibodies lead to
phagocytosis of target cells (i.e., leukemia cells and healthy HSPCs). Antibody−drug conjugates cause direct toxicity of target antigen-positive
cells. Bispecific T cell-engaging antibodies redirect cytotoxic T cell toward target cells. CAR T cells are gene-engineered to express a synthetic
chimeric receptor, which enables a surface antigen-directed attack of target cells. (B) Fraction of bone marrow cells during treatment of an
AML patient with conventional chemotherapy, anti-CD117 conditioning, and allogeneic stem cell transplantation. AML cells are shown in red,
healthy patient hematopoiesis in blue, donor-derived hematopoiesis in yellow. Solid lines represent mature cells; dashed lines represent progeni-
tor cells.
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immune barrier facilitates engraftment of donor cells; and (3)
low-level chimerism might likely be sufficient for restoration
of immune function. According to early reports, stable donor-
derived HSC chimerism has been achieved in these patients
with very limited toxicity. With this proof of safety and feasi-
bility, the product was licensed to Jasper Therapeutics, which
aims to advance the antibody to broader patient populations.
Currently, patients with AML or MDS will receive JSP191 in
addition to a conventional conditioning regime prior to alloge-
neic stem cell transplantation [138].
Outline of a trial for anti-CD117 immunotherapy
and subsequent HSCT
All anti-CD117−directed immunotherapies will have
significant toxicity against healthy HSCs. Therefore,
the inclusion in pretransplant conditioning regimes is
the ideal setting to evaluate safety and toxicity, as was
done in the Jasper trial [138]. For bispecific antibodies
or CAR T cells, we envision a first clinical application
in AML and MDS patients with high risk of relapse
who have achieved a complete morphologic remission
with detectable MRD after standard therapy. Standard
chemotherapy allows for debulking of the disease on
the one hand and for production of CAR T cells or
regeneration of autologous lymphocytes on the other.
In this particular setting, less than 5% of blasts are
present in bone marrow of patients, allowing for a
favorable effector-to-target ratio [139]. Yet, direct
response to anti-CD117 immunotherapeutic agents can
be assessed by molecular quantification of MRD. Infu-
sion of anti-CD117 CAR T cells or bispecific antibod-
ies would therefore be carried out with a sufficient
time gap prior to conventional conditioning chemother-
apy. This would allow for analysis of potential toxicity
and efficacy. We estimate that a window of 1−4 weeks
will be required for sufficient activity of either CAR T
cells or bispecific antibodies.
Figure 2B illustrates the application of anti-CD117
immunotherapies in the context of a potential treatment
concept. Subsequent trials could be aimed at decreasing
the standard conditioning regimens if the approach
proves to be sufficient to eliminate healthy HSCs.
Potential limitations
Some inherent limitations of anti-CD117 conditioning
are evident. The data on unarmed IgG antibodies and
ADCs indicate depletion of the majority of CD117-pos-
itive cells; however, a significant fraction remains.
Additionally, more aggressive stem cell malignancies
such as high-risk MDS and AML evade immune mech-
anisms and might require higher effector strength.
Anti-CD117 CAR T cells harbor that potency; how-
ever, they might take too much time. Preclinical data
in myeloid and clinical data in B-cell malignancies
indicate that CAR T cells require a longer time frame
from 1 to 6 months to achieve their full potential [140,141].
B-Cell aplasia is a surrogate parameter for CD19 CAR T-cell
activity, and B-cell aplasia of less than two months correlates
with high relapse rates, indicating the requirement for
extended presence and immunologic activity of CAR T cells.
Prolonged HSC aplasia, for obvious reasons, is not a desirable
endpoint and might limit the applicability of CAR T cells in
myeloid malignancies. Another aspect of concern for CD117-
directed T cell−mediated immunotherapy is the potential
impairment of quantity and fitness of patient-derived T cells
after AML/MDS and intensive chemotherapy. Patients who
do not achieve complete remission might be an even more
challenging patient cohort because of the larger number of tar-
get cells and the inflammatory perturbations in the bone
microenvironment.
Also, given the broad expression of CD117 in non-hemato-
poietic tissues (Figure 1), the absence of systemic side effects
in preclinical models and in the clinical trials seems astonish-
ing. Whereas JSP191 merely blocks binding of SCF, both
SR-1 and ACK2 do have Fc-mediated effector functions
[91,92,95,105,106]. However, no serious side effects were
observed in mice and non-human primates
[83,94,95,97,102,107,108]. Also, mouse anti-CD117 ADC
and CAR T cells were tolerated in immunocompetent mice
without off-target effects [120−122,133]. The CD117 expres-
sion patterns in mice and humans are comparable; however,
the respective antibody or antibody fragments differ [69]. A
mouse model with expression of human CD117 is currently
not reported. Therefore, in clinical trials with anti-CD117
CAR T cells or bispecific antibodies, there will be a special
emphasis on potential on-target, off-tumor side effects in, for
example, the central nervous system, gonads, skin, and kid-
neys. For entirely non-genotoxic conditioning concepts in
immunocompetent humans, additional obstacles need to be
considered. Host-versus-graft immunity against transplanted
HSCs needs to be overcome. It remains to be seen if purely
antibody-based concepts for depletion of T/NK cell−medi-
ated immunity are readily translatable from mice to humans.
For CAR T cell−mediated conditioning, definitive eradica-
tion of the anti-CD117 effector cells prior to infusion of the
graft is another concern that has not yet been solved. Addi-
tionally, with the fast-moving pace of biological and medical
discoveries, other treatment concepts, such as targeting of the
CD70/CD27 axis, might lead the way.
Scenarios of use outside AML treatment
Immunologic conditioning could not only revolutionize
the treatment of rare hematological malignancies. The
range of potential applications of safer hematopoietic
stem cell transplantation is wide, as reviewed else-
where [142−145]. In particular, the combination with
current and future gene modification technologies will
enable transplantation with autologous gene-corrected
hematopoietic stem cells for the treatment of genetic
disorders such as sickle cell disease, chronic
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granulomatous disease (CGD), and thalassemia. Fur-
thermore, allogeneic stem cell transplantation could be
used to generate mixed donor chimerism and might
enable solid organ transplantation independent of HLA
barriers. Lastly, aggressive systemic mastocytosis is
inherently positive for CD117 and might be within the
scope of CD117 immunotherapies [146].
Summary and outlook
About 30 years ago, CD117 was discovered as the
receptor for stem cell factor [111,147,148]. One gener-
ation later, specific binders have been developed and
optimized, and potential clinical applications have been
identified and are being evaluated in clinical trials. At
the end of this first generation, the feasibility of immu-
nologic conditioning has been demonstrated, and the
future potential seems vast. However, efficacy needs to
be demonstrated in immunocompetent humans. Five
years from now, we will have learned lessons from the
current clinical trials using first-generation anti-CD117
targeting agents. It remains to be seen if efficacy of
unarmed IgG antibodies is sufficient for depletion of
malignant hematopoietic cells. If malignant hematopoi-
etic diseases are resistant, it will be a challenge to
increase cytotoxic efficacy, for example, by application
of anti-CD117 CAR T cells or bispecific antibodies,
without increasing inherent toxicity. Most likely, evi-
dence from clinical trials will lead to another round of
fine-tuning of anti-CD117 agents and their combinato-
rial use in basic research and preclinical models. At
the same time, progress in gene editing technology will
broaden the scope of diseases that can be tackled by
transplantation of gene-edited autologous HSC. In 10
years‘ time, we might see the second round of clinical
translation of optimized anti-CD117 agents for treat-
ment of malignant hematological diseases, as well as
for conditioning prior to autologous transplantation. It
will take time and effort before anti-CD117 agents will
make traditional conditioning regimens obsolete.
In conclusion, the demand for optimized and less
toxic conditioning concepts is obvious and diverse
approaches targeting CD117 on HSCs are among the
frontrunners of this development. If progress in the
field continues at the current pace, we might reach an
era of regenerative medicine in which targeted and spe-
cific “precision replacement and regeneration” of dis-
eased HSCs with allogeneic or gene-edited autologous
HSCs becomes reality.
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